| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Boceprevir for untreated chronic HCV genotype 1 infection.
|
N Engl J Med
|
2011
|
19.01
|
|
2
|
Sofosbuvir for previously untreated chronic hepatitis C infection.
|
N Engl J Med
|
2013
|
13.30
|
|
3
|
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
|
N Engl J Med
|
2009
|
12.07
|
|
4
|
Telaprevir for previously treated chronic HCV infection.
|
N Engl J Med
|
2010
|
8.33
|
|
5
|
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
|
N Engl J Med
|
2014
|
8.13
|
|
6
|
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
|
Lancet
|
2012
|
6.93
|
|
7
|
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
|
Lancet
|
2010
|
6.52
|
|
8
|
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
|
Gastroenterology
|
2010
|
6.14
|
|
9
|
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
|
N Engl J Med
|
2014
|
3.40
|
|
10
|
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
|
Lancet
|
2013
|
3.40
|
|
11
|
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
|
Lancet Infect Dis
|
2013
|
3.30
|
|
12
|
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
|
N Engl J Med
|
2015
|
3.16
|
|
13
|
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
|
Hepatology
|
2008
|
3.14
|
|
14
|
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.
|
Clin Gastroenterol Hepatol
|
2008
|
2.97
|
|
15
|
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C.
|
Hepatology
|
2008
|
2.81
|
|
16
|
Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.
|
Am J Gastroenterol
|
2002
|
2.55
|
|
17
|
Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.
|
Brain Behav Immun
|
2005
|
2.52
|
|
18
|
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C.
|
Blood
|
2005
|
2.50
|
|
19
|
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset.
|
Blood
|
2011
|
2.49
|
|
20
|
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.
|
Clin Gastroenterol Hepatol
|
2007
|
2.16
|
|
21
|
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.
|
Hepatology
|
2014
|
2.04
|
|
22
|
Factors that predict response of patients with hepatitis C virus infection to boceprevir.
|
Gastroenterology
|
2012
|
1.95
|
|
23
|
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.
|
Clin Gastroenterol Hepatol
|
2006
|
1.92
|
|
24
|
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.
|
Hepatology
|
2007
|
1.73
|
|
25
|
Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia.
|
Blood
|
2007
|
1.72
|
|
26
|
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.
|
Clin Infect Dis
|
2013
|
1.62
|
|
27
|
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.
|
J Hepatol
|
2011
|
1.59
|
|
28
|
Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.
|
J Clin Psychiatry
|
2005
|
1.58
|
|
29
|
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States.
|
Clin Gastroenterol Hepatol
|
2004
|
1.47
|
|
30
|
HIV/hepatitis C virus-coinfected patients with normal alanine aminotransferase levels.
|
J Acquir Immune Defic Syndr
|
2006
|
1.44
|
|
31
|
Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection.
|
J Infect Dis
|
2009
|
1.36
|
|
32
|
Presence of functional dendritic cells in patients chronically infected with hepatitis C virus.
|
Blood
|
2003
|
1.33
|
|
33
|
Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C.
|
J Infect Dis
|
2005
|
1.31
|
|
34
|
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.
|
Clin Infect Dis
|
2012
|
1.20
|
|
35
|
Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients.
|
J Immunol
|
2003
|
1.19
|
|
36
|
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.
|
PLoS One
|
2012
|
1.19
|
|
37
|
Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C.
|
Clin Infect Dis
|
2012
|
1.14
|
|
38
|
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
|
Hepatology
|
2014
|
1.10
|
|
39
|
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.
|
Gastroenterology
|
2012
|
1.09
|
|
40
|
Emerging therapies for the treatment of hepatitis C.
|
EMBO Mol Med
|
2014
|
1.09
|
|
41
|
New and experimental therapies for HCV.
|
Nat Rev Gastroenterol Hepatol
|
2009
|
1.05
|
|
42
|
Daclatasvir plus sofosbuvir for HCV infection.
|
N Engl J Med
|
2014
|
1.04
|
|
43
|
Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.
|
Hepatology
|
2013
|
1.03
|
|
44
|
Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.
|
Am J Gastroenterol
|
2003
|
1.02
|
|
45
|
Managing patients with hepatitis‑B-related or hepatitis‑C-related decompensated cirrhosis.
|
Nat Rev Gastroenterol Hepatol
|
2011
|
1.02
|
|
46
|
Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree?
|
Med Decis Making
|
2008
|
1.02
|
|
47
|
Telaprevir-based treatment effects on hepatitis C virus in liver and blood.
|
Hepatology
|
2014
|
0.99
|
|
48
|
Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality.
|
Am J Gastroenterol
|
2003
|
0.95
|
|
49
|
Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients.
|
J Acquir Immune Defic Syndr
|
2004
|
0.95
|
|
50
|
Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop.
|
Am J Gastroenterol
|
2010
|
0.95
|
|
51
|
The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
|
Antivir Ther
|
2012
|
0.94
|
|
52
|
Customizing the management of chronic hepatitis B virus infection.
|
Semin Liver Dis
|
2007
|
0.92
|
|
53
|
How to use statins in patients with chronic liver disease.
|
Cleve Clin J Med
|
2004
|
0.89
|
|
54
|
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.
|
Antivir Ther
|
2013
|
0.88
|
|
55
|
Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial.
|
J Clin Gastroenterol
|
2011
|
0.86
|
|
56
|
Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin.
|
Dig Dis Sci
|
2007
|
0.84
|
|
57
|
Seizures during pegylated interferon and ribavirin therapy for chronic Hepatitis C: observations from the WIN-R trial.
|
J Clin Gastroenterol
|
2011
|
0.83
|
|
58
|
Advances in the treatment of hepatitis C virus infection.
|
Gastroenterol Hepatol (N Y)
|
2012
|
0.83
|
|
59
|
The role of the woodchuck model in the treatment of hepatitis B virus infection.
|
Clin Liver Dis
|
2007
|
0.82
|
|
60
|
Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy.
|
Semin Liver Dis
|
2007
|
0.82
|
|
61
|
Combination therapy for chronic hepatitis B: ready for prime time?
|
J Hepatol
|
2008
|
0.82
|
|
62
|
Resistance-associated variants in chronic hepatitis C patients treated with protease inhibitors.
|
Curr Gastroenterol Rep
|
2012
|
0.81
|
|
63
|
IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.
|
J Acquir Immune Defic Syndr
|
2013
|
0.81
|
|
64
|
Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy.
|
PLoS One
|
2013
|
0.81
|
|
65
|
Emerging therapeutic targets for hepatitis C virus infection.
|
Clin Gastroenterol Hepatol
|
2013
|
0.80
|
|
66
|
Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.
|
Clin Gastroenterol Hepatol
|
2012
|
0.80
|
|
67
|
Cardiovascular diseases and the liver.
|
Clin Liver Dis
|
2011
|
0.80
|
|
68
|
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C.
|
Antivir Ther
|
2014
|
0.79
|
|
69
|
Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response.
|
Value Health
|
2012
|
0.79
|
|
70
|
VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection.
|
Eur J Gastroenterol Hepatol
|
2014
|
0.78
|
|
71
|
Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein.
|
Liver Int
|
2004
|
0.78
|
|
72
|
Telaprevir: hope on the horizon, getting closer.
|
Clin Liver Dis
|
2009
|
0.78
|
|
73
|
Entering the new era of therapy for HBV and HCV infections.
|
J Fam Pract
|
2010
|
0.77
|
|
74
|
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml).
|
Liver Int
|
2014
|
0.77
|
|
75
|
Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.
|
J Acquir Immune Defic Syndr
|
2011
|
0.77
|
|
76
|
Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
|
J Clin Gastroenterol
|
2014
|
0.77
|
|
77
|
Advancing patient care: integrating new data.
|
Am J Gastroenterol
|
2006
|
0.76
|
|
78
|
WIN-R revisited: Response to editorial.
|
Hepatology
|
2008
|
0.75
|
|
79
|
Liver disease. The influence of SOCS3 expression on the treatment response of HCV-related chronic hepatitis patients.
|
Rev Gastroenterol Disord
|
2008
|
0.75
|
|
80
|
Chronic hepatitis C genotype 2 and 3: are we ready for personalized medicine?
|
J Hepatol
|
2011
|
0.75
|
|
81
|
Fenofibrate-induced cirrhosis.
|
Dig Dis Sci
|
2005
|
0.75
|
|
82
|
The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation.
|
Cleve Clin J Med
|
2004
|
0.75
|
|
83
|
Treatment of relapsers after combination therapy for chronic hepatitis C.
|
Gastroenterol Clin North Am
|
2004
|
0.75
|
|
84
|
Telaprevir for chronic hepatitis C virus infection.
|
Clin Liver Dis
|
2013
|
0.75
|
|
85
|
Treatment of relapsers after combination therapy for chronic hepatitis C.
|
Infect Dis Clin North Am
|
2006
|
0.75
|
|
86
|
Optimal treatment with telaprevir for chronic HCV infection.
|
Liver Int
|
2013
|
0.75
|
|
87
|
Clinical course of chronic hepatitis C in patients with very high serum alpha-fetoprotein levels and normal hepatic imaging.
|
Am J Gastroenterol
|
2005
|
0.75
|
|
88
|
Halting the natural history of hepatitis B viral infection: a paradigm shift.
|
Semin Liver Dis
|
2007
|
0.75
|
|
89
|
Screening and diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis.
|
Rev Gastroenterol Disord
|
2009
|
0.75
|
|
90
|
Slowing the progression of chronic hepatitis B. Early antiviral therapy can help minimize complications.
|
Postgrad Med
|
2003
|
0.75
|
|
91
|
Role of the nurse practitioner in the management of patients with chronic hepatitis C.
|
J Am Acad Nurse Pract
|
2011
|
0.75
|